HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma

An Open-Label Therapeutic Exploratory Clinical Trial of HuMax-CD4, a Fully Human Monoclonal Anti-CD4 Antibody, in Patients With Refractory or Relapsed Non-Cutaneous CD4+ T-Cell Lymphoma

The purpose of this study is to assess the safety and efficacy of treatment of non-cutaneous T-cell lymphoma with treatment with CD4.

The study is closed and all subjects have completed treatment.

The study is to evaluate the safety and efficacy of Humax CD4 with CHO vs CHO alone in subjects with non-cutaneous T cell lymphoma. The primary efficacy will be evaluated by time to relapse.

Inclusion Criteria:

• Diagnostic biopsy of non cutaneous T Cell lymphoma with positive phenotype
• Relapsed or refractory to minimum of one course of chemotherapy
• Study is closed to enrollment.